医学
列线图
内科学
比例危险模型
结直肠癌
多元分析
阶段(地层学)
结肠切除术
癌胚抗原
外科肿瘤学
单变量分析
生存分析
肿瘤科
胃肠病学
癌症
古生物学
生物
作者
Yunzhou Xiao,Xiaoting Wen,Yingying Ying,Xiaoyan Zhang,Luyao Li,Wang Zhong-chu,Miaoguang Su,Shouliang Miao
出处
期刊:BMC Cancer
[Springer Nature]
日期:2024-04-06
卷期号:24 (1)
标识
DOI:10.1186/s12885-024-12208-7
摘要
Abstract Objective The objective of this study was to investigate the correlation between spleen density and the prognostic outcomes of patients who underwent curative resection for colorectal cancer (CRC). Methods The clinical data of patients who were diagnosed with CRC and underwent radical resection were retrospectively analyzed. Spleen density was determined using computed tomography. Analysis of spleen density in relation to overall survival (OS) and disease-free survival (DFS) utilizing the Kaplan–Meier method. Univariate and multivariate Cox regression models were used to screen for independent prognostic factors, and a nomogram was constructed to predict OS and DFS. Moreover, internally validated using a bootstrap resamplling method. Results Two hundred twelve patients were included, of whom 23 (10.85%) were defined as having a diffuse reduction of spleen density (DROSD) based on diagnostic cutoff values (spleen density≦37.00HU). Kaplan–Meier analysis indicated that patients with DROSD had worse OS and DFS than those non-DROSD ( P < 0.05). Multivariate Cox regression analysis revealed that DROSD, carbohydrate antigen 199 (CA199) > 37 U/mL, tumor node metastasis (TNM) stage III-IV, laparoscopy-assisted operation and American Society of Anesthesiology (ASA) score were independent risk factors for 3-year DFS. DROSD, CA199 > 37 U/mL, TNM stage III-IV, hypoalbuminemia, laparoscopy-assisted operation and ASA score were chosen as predictors of for 3-year OS. Nomograms showed satisfactory accuracy in predicting OS and DFS using calibration curves, decision curve analysis and bootstrap resamplling method. Conclusion Patients with DROSD who underwent curative resection have worse 3-year DFS and OS. The nomogram demonstrated good performance, particularly in predicting 3-year DFS with a net clinical benefit superior to well-established risk calculator.
科研通智能强力驱动
Strongly Powered by AbleSci AI